Skip to main content

Milestone Pharmaceuticals Inc.

MIST
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001408443

No open-market purchases or sales by Milestone Pharmaceuticals Inc. insiders were filed in the last 90 days; 73 institutions reported holding it in 13F filings for Q3 2026, worth $43.6M in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 14, 2026, 1:24 AM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of Milestone Pharmaceuticals Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 20, 2026Mar 13, 2025Mar 21, 2024Mar 29, 2023Mar 24, 2022
Research and development$18.1M$14.4M$31.1M$39.8M$38.7M
Selling, general and administrative$17.3M$16.7M$15.9M$15.7M$12.4M
Operating income-$62.1M-$42.1M-$61.1M-$59.6M-$43.1M
Interest expense––$2.55M––
Net income-$63.1M-$41.5M-$59.7M-$58.4M-$42.9M
EPS, basic$-0.75$-0.67$-1.39$-1.38$-1.02
EPS, diluted$-0.75$-0.67$-1.39–$-1.02

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Milestone Pharmaceuticals Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 20, 2026Mar 13, 2025Mar 21, 2024Mar 29, 2023Mar 24, 2022
Cash and equivalents$73.0M$25.3M$13.8M$7.64M$114.1M
Short-term investments$32.9M$44.4M$52.2M$56.9M$0
Inventory$648.0K––––
Total current assets$111.9M$73.9M$73.0M$71.8M$118.9M
Property, plant and equipment$511.0K$197.0K$277.0K$257.0K$215.0K
Total assets$113.6M$75.5M$75.2M$74.5M$119.8M
Total current liabilities$14.0M$8.13M$7.23M$6.14M$6.78M
Long-term debt$57.2M$53.4M$49.8M––
Total liabilities$71.8M$62.4M$58.5M$8.13M$7.25M
Shareholders' equity$41.8M$13.1M$16.8M$66.3M$112.6M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Milestone Pharmaceuticals Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 20, 2026Mar 13, 2025Mar 21, 2024Mar 29, 2023Mar 24, 2022
Operating cash flow-$49.0M-$28.8M-$46.4M-$52.5M-$33.2M
Capital expenditures$302.0K$33.0K$112.0K$272.0K–
Free cash flow-$49.3M-$28.9M-$46.5M-$52.7M–
Depreciation and amortization$114.0K$105.0K$92.0K$89.0K$93.0K
Stock-based compensation$7.46M$5.78M$9.53M$9.05M$7.28M
Investing cash flow$11.2M$8.28M$4.76M-$57.1M$70.0M
Financing cash flow$85.5M$32.1M$47.8M$3.09M$5.05M
Net change in cash$47.7M$11.6M$6.12M-$106.5M$41.8M

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Milestone Pharmaceuticals Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 13, 2026124.5M+46.2%SEC
Aug 12, 2026124.5M+46.5%SEC
May 13, 2026124.5M+132.9%SEC
Mar 20, 2026117.7M+120.5%SEC
Nov 12, 202585.2M+59.7%SEC
Aug 12, 202585.0M+59.6%SEC
May 14, 202553.5M+0.4%SEC
Mar 13, 202553.4M+0.4%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS. Their cover share count adds up the classes but only for the last few filings, so there can be a gap before them.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.